Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Genzyme resubmits MS drug for FDA approval

Cambridge biotech Genzyme said Friday that it has resubmitted its application for a cdrug called Lemtrada that was rejected by the Food and Drug Administration in December.

In a press release, Genzyme said it had resubmitted the application “earlier this month following constructive discussions with the agency.”

Continue reading below

Genzyme said a six-month review period has been assigned for Lemtrada and added that it expects the FDA to take action on the resubmitted application in the fourth quarter.

The potential for Lemtrada was among the reasons why French drug maker Sanofi SA acquired Genzyme in 2011 for $20.1 billion. As part of that deal, Sanofi agreed to reward former Genzyme stockholders if the drug achieved certain milestones in the US market regarding approval and sales.

But even though the drug has now been approved by regulators in the European Union, Australia, Brazil, Canada, Mexico, and Guatemala, the FDA questioned the integrity of Lemtrada’s clinical trials and cited the risk of potentially serious side effects in its December rejection.

At that time, a Genzyme executive indicated that the company might appeal the FDA ruling. But in April, the company said it would file an updated application that would specifically address issues raised by the FDA.

In its Friday release, Genzyme said it submitted an updated application earlier this month.

Genzyme scientists spent more than a decade developing Lemtrada for the treatment of multiple sclerosis, a disease that affects the central nervous system. About 1,700 patients were involved in clinical testing of the drug. More than 2.3 million people have been diagnosed with MS worldwide, including about 400,000 in the United States.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week